Aeterna Zentaris GmbH
Records under this name other than the patents Aeterna Zentaris GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,710,089 | Triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors Lapsed on the fee record Ended Apr 29, 2026 · USPTO record | Lapsed on the fee record | Ended Apr 29, 2026 | USPTO record |
| US 8,669,091 | Microorganisms as Carriers of Nucleotide Sequences Coding for Antigens and Protein Toxins, Process of Manufacturing and Uses Thereof Formerly held Lapsed on the fee record Ended Mar 11, 2026 · High confidence | Lapsed on the fee record | Ended Mar 11, 2026 | High confidence |
| US 8,546,435 | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors Lapsed on the fee record Ended Oct 1, 2025 · High confidence | Lapsed on the fee record | Ended Oct 1, 2025 | High confidence |
| US 7,887,817 | Process for preventing protozoal diseases Term ended Term ended Dec 22, 2024 · USPTO record | Term ended | Term ended Dec 22, 2024 | USPTO record |
| US 8,551,977 | Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals Term ended Term ended Jan 31, 2024 · USPTO record | Term ended | Term ended Jan 31, 2024 | USPTO record |
| US 7,214,662 | Injectable solution of an LHRH antagonist Formerly held Term ended Term ended Oct 29, 2023 · USPTO record | Term ended | Term ended Oct 29, 2023 | USPTO record |
| US 7,790,686 | Injection solution of an LHRH antagonist Formerly held Term ended Term ended Oct 28, 2023 · USPTO record | Term ended | Term ended Oct 28, 2023 | USPTO record |
| US 8,389,497 | Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals Formerly held Term ended Ended no later than Jul 30, 2023 · USPTO record | Term ended | Ended no later than Jul 30, 2023 | USPTO record |
| US 6,861,409 | Growth hormone secretagogues Term ended Term ended Aug 1, 2022 · USPTO record | Term ended | Term ended Aug 1, 2022 | USPTO record |
| US 7,297,681 | Growth hormone secretagogues Term ended Term ended Aug 1, 2022 · USPTO record | Term ended | Term ended Aug 1, 2022 | USPTO record |